From Business Week, “Myriad Genetics falls as gene patents are voided“,
“[…] a court overturned a group of patents on gene sequences linked to breast cancer and ovarian cancer, which Myriad uses in tests for those diseases.
Myriad Genetics sells a test for mutations on the two breast cancer predisposition genes, which are called BRCA1 and BRCA2, and says those mutations are connected to greatly increased risks of cancer. The company holds patents on several DNA sequences from the gene, but its patents were challenged a year ago in a lawsuit by the American Civil Liberties Union and other groups. On Monday, a U.S. District Court Judge ruled against the Myriad Genetics.”
More info from the gene patent page at Wikipedia.
Filed under: Health Sciences & Medicine, patent 
